Strong CYP3A4 inhibitor that also inhibits OATP1B; avoid concomitant use as it significantly increases FOUNDAYO plasma concentrations and risk of adverse reactions.
Source: NLP:orforglipron
Orforglipron Interactions
4 interactions on record
Do not exceed simvastatin 20 mg once daily; concomitant use increases simvastatin acid exposure two-fold, which may be clinically meaningful.
Source: NLP:orforglipron
Orforglipron + Insulin HumanModerate
When initiating FOUNDAYO, consider reducing the dose of concomitantly administered insulin due to potential additive effects on glucose lowering.
Source: NLP:orforglipron
Orforglipron + SulfonylureaModerate
When initiating FOUNDAYO, consider reducing the dose of concomitantly administered sulfonylureas due to potential additive effects on glucose lowering.
Source: NLP:orforglipron